RegCell is a biotechnology company developing first-in-class cell therapies to restore immune tolerance, based on Nobel laureate Shimon Sakaguchi's discovery of regulatory T cells. Its proprietary epigenetic reprogramming platform converts disease-causing immune cells into stable, antigen-specific regulatory T cells.